Phase 2 Start

NBIX: Phase2_Start: A Phase 2, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adults With Classic Congenital Adrenal Hyperplasia

Name: Phase2_Start: A Phase 2, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adults With Classic Congenital Adrenal Hyperplasia
Start: 2026-12-01
End: 2026-12-01

December 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2026
Company: NEUROCRINE BIOSCIENCES INC (NBIX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start

Phase2_Start: A Phase 2, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adults With Classic Congenital Adrenal Hyperplasia

December 1, 2026

NBIX overview →

Company: NEUROCRINE BIOSCIENCES INC (NBIX)